Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
241-260 of 991 trials

Metastatic Non-Small Cell Lung Cancer: ONC-392 vs. Docetaxel

We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Stomach Cancer: MK-2870 Treatment Study

We are comparing a new treatment called MK-2870 to standard care for people with advanced stomach cancer. The goal is to see if MK-2870 can improve survival and manage symptoms better.

Adenocarcinoma of the Gastroesophageal Junction>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementGastroenterologyOncology

Memory Disorders: Evaluating Tau PET Imaging

We are studying whether tau PET can improve diagnosis for patients with memory problems. This trial compares its effectiveness to more common and affordable diagnostic tools.

Mild Cognitive Impairment and Dementia1-2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementNeurology

Heart Attack Prevention: Selatogrel Study

We are studying whether self-administering selatogrel can help prevent further heart attacks in individuals with a recent heart attack history. The trial also looks at the safety of this self-administration.

Heart Attack>2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Erosive Esophagitis: NEXIUM for Kids

We are studying whether NEXIUM can help maintain healing in children aged 1 to 11 with erosive esophagitis. This trial also looks at how well the medication works and any symptoms during treatment.

Erosive Esophagitis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Sparsentan for Pediatric Kidney Diseases

We are studying a new oral treatment for children with certain kidney diseases to see if it is safe and effective. The trial will also evaluate how well children tolerate the medication and its impact on kidney function.

Proteinuric Glomerular Diseases>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Long-term Safety Study for Ciltacabtagene Autoleucel

We are following up with patients who received cilta-cel to learn about any long-term side effects and how well the treatment works over time. This study aims to improve our understanding of the treatment's safety and effectiveness.

Multiple Myeloma>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology

Pulmonary Arterial Hypertension: Treprostinil Palmitil Inhalation Powder

We are studying the long-term safety and effects of an inhalation powder for people with pulmonary arterial hypertension. This research aims to see if it improves exercise capacity and overall health.

Pulmonary Arterial Hypertension1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Carcinoma of Unknown Primary: [18F]F-FAPI PET-CT Study

We are investigating whether [18F]F-FAPI PET-CT can help identify the primary tumor in patients with carcinoma of unknown primary. This study aims to improve diagnosis and treatment options for these patients.

Carcinoma of Unknown Primary>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Spinal Muscular Atrophy: Risdiplam Study for Infants

We are investigating how the medication risdiplam works and its safety in infants with spinal muscular atrophy. This study aims to provide important insights into its use for this condition.

Spinal Muscular Atrophy1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics

Head and Neck Cancer: Ficlatuzumab and Cetuximab Study

We are investigating whether the combination of ficlatuzumab and cetuximab improves survival in adults with recurrent or metastatic HPV-negative head and neck cancer. This study compares the effects of this combination to a placebo treatment.

Head and Neck Squamous Cell Carcinoma>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncology

B-Cell Non-Hodgkin’s Lymphoma: Glofitamab and Obinutuzumab Study

We are studying the safety and effectiveness of Glofitamab alone and with Obinutuzumab in patients with relapsed or refractory B-cell Non-Hodgkin’s Lymphoma. This trial aims to find the best dose and understand how these treatments work together.

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Chronic Kidney Disease: Patiromer Study

We are testing whether patiromer helps patients with chronic kidney disease better manage their blood pressure and reduce protein in urine. This study aims to improve treatment options for those with advanced kidney disease.

Chronic Kidney Disease6-12 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyNephrology

Lupus Treatment: BIIB059 Study

We are testing a new medication, BIIB059, for people with active subacute or chronic cutaneous lupus who haven't responded to standard treatments. The study aims to see if it can reduce skin disease activity and improve overall safety.

Skin Lupus1-2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatologyRheumatology

Atypical Hemolytic Uremic Syndrome: Crovalimab for Kids

We are studying the safety and effectiveness of crovalimab in children with atypical hemolytic uremic syndrome. This trial includes both new patients and those switching from other treatments.

Atypical Hemolytic Uremic Syndrome6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyNephrology

Hypophosphatasia in Children: ALXN1850 Study

We are studying a new treatment, ALXN1850, for children with hypophosphatasia who haven't been treated before. The goal is to see if it improves bone health and quality of life compared to a placebo.

Hypophosphatasia3-6 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOrthopedics and TraumatologyPediatrics

Ulcerative Colitis: Lutikizumab Treatment Study

We are assessing the safety and effectiveness of lutikizumab in adults with active ulcerative colitis. This study compares it to an existing treatment to see if it offers better results.

Ulcerative Colitis1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Advanced Non-Small Cell Lung Cancer: OSIBOOST 2 Study

We are testing a modified dosing strategy of osimertinib, with or without a booster drug, for patients with advanced EGFR mutated NSCLC. This study aims to improve treatment cost-effectiveness and reduce side effects while maintaining effectiveness.

Non-Small Cell Lung Cancer with an EGFR Mutation≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementOncologyPulmonology

Lung Cancer Treatment: Telisotuzumab Vedotin vs. Docetaxel

We are studying a new intravenous treatment for adults with previously treated non-squamous non-small cell lung cancer. The trial aims to see if it improves survival and quality of life compared to standard therapy.

Non-Squamous Non-Small Cell Lung CancerConfirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Hereditary Angioedema: PHA-022121 Treatment Study

We are testing the safety of a new oral medication for treating acute angioedema attacks in patients with hereditary angioedema. The study will also evaluate how well it relieves symptoms during these attacks.

Hereditary AngioedemaEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine